Adma Biologics Inc (NASDAQ:ADMA) Shares Shorted Increased By 11.05%

April 17, 2018 - By Darrel Chase

ADMA Biologics, Inc. (NASDAQ:ADMA) Corporate Logo

Big Money Sentiment increased to 3 in 2017 Q4. It has change of 1.86, from 2017Q3’s 1.14. The ratio is positive due to ADMA Biologics, Inc. positioning: 4 sold and 2 reduced. 8 funds bought holdings and 10 increased holdings. Investors holded 7.02 million in 2017Q3 but now own 15.53 million shares or 121.29% more.
Morgens Waterfall Vintiadis & Inc has invested 1.26% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Ontario – Canada-based Royal Bancorporation Of Canada has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Perceptive Advsrs Ltd holds 0.41% or 3.82M shs in its capital. Consonance Cap Mgmt L P holds 0.98% or 3.37 million shs. Advisory Svcs Net Ltd owns 700 shs. Morgan Stanley invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Aisling Capital Ltd Liability reported 2.29% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Broadfin Ltd Liability, New York-based fund reported 1.10M shs. Millennium Management owns 67,533 shs. Highbridge Cap Mgmt Ltd Llc holds 0.02% or 312,500 shs. Moreover, Northern Trust has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 31,405 shs. Iguana Health Mngmt Ltd Liability Corporation holds 1.25% or 600,000 shs in its capital. Geode Ltd Liability Com has invested 0% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). 23,188 were accumulated by Virtu Financial Limited Liability. Blackrock stated it has 25,421 shs.

Change of 11.05% for Adma Biologics Inc (NASDAQ:ADMA)’s shorted shares was registered. It was published in April by FINRA the 133,700 shorted shares on ADMA. Previously was reported up change of 11.05% from 120,400 shares. Previous ADMA’s position will need 1 days to recover. It has 198,000 average volume. Float short on Adma Biologics Inc is 1.37%.

Its shares touched $5.07 on during the last trading session after 2.50% change.ADMA Biologics, Inc. has volume of 62,415 shares. Since April 17, 2017 ADMA has risen 0.20% and is uptrending. The stock underperformed the S&P500 by 11.35%.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases.The firm is worth $229.76 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease.Last it reported negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.